Pappas Ventures
VC Fund
Durham, United States
Pappas Ventures is a VC fund in Durham focused on Biotechnology and Health Care. Pappas Ventures provides investment in the life sciences sector.
- Total investments:
- 42
- Last investment:
- Lead investor:
- 7%
Last updated:
For AI agents: llms.txt
Industries Pappas Ventures invests in
BiotechnologyHealth CareTherapeuticsPharmaceuticalMedical Device
Stages Pappas Ventures invests in
Series ASeries BSeries CSeries DFunding Round
Countries Pappas Ventures invests in
United StatesCanada
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Mike Grey
|
|||
| See all 8 contacts → | |||
Investment Focus
Industry
- Biotechnology 24 (57%)
- Health Care 22 (52%)
- Therapeutics 14 (33%)
- Pharmaceutical 11 (26%)
- Medical Device 7 (17%)
Stage
- Series A 10 (24%)
- Series B 8 (19%)
- Series C 6 (14%)
- Series D 5 (12%)
- Funding Round 3 (7%)
Country
- United States 26 (62%)
- Canada 2 (5%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Eric W. Linsley
Partner
|
Partner | Total investments: 7 | Find email | |
Ford Worthy
Partner
|
Partner | Total investments: 2 | Find email | |
Franz Humer
Venture partner and Senior editor
|
Venture partner and Senior editor | Total investments: 3 | Find email | |
|
Mike Grey
Venture Partner
|
Venture Partner | Total investments: 1 | Find email | |
Artthur M. Pappas
Founder, CEO & Managing General Partner
|
Founder, CEO & Managing General Partner | Total investments: 12 | Find email | |
| See all 8 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Kezar Life Sciences
|
Kezar Life Sciences company focused on the discovery and development of drugs targeting protein homeostasis for autoimmune disorders. In parallel with this work, Christopher and Kezar co-founder Jack Taunton, Ph.D. collaborated on several research projects involving protein secretion. This collaboration inspired a belief in the strong synergiesbetween protein degradation and protein secretion, two fertile areas for drug discovery with platform potential. | $50M / Series B / Jul 25, 2017 | |
Evidation Health
|
Evidation measures health in everyday life and enables anyone to participate in groundbreaking research and health programs. Built upon a foundation of user privacy and control over permissioned health data, Evidation's Achievement platform is trusted by millions of individuals—generating data with unprecedented speed, scale, and rigor. Wepartner with leading healthcare companies to understand health and disease outside the clinic walls. Guided by our mission to enable and empower everyone to participate in better health outcomes, Evidation is working to bring people individualized, proactive, and accessible healthcare—faster. Founded in 2012, Evidation Heath is headquartered in California. We collaborate as a distributed team with additional offices around the globe. To learn more, visit evidation.com, or follow us on Twitter @evidation | $3.4M / Series B / Oct 11, 2016 | |
Milestone Pharmaceuticals
|
Milestone Pharmaceuticals is a drug development company developing novel small molecule therapeutics based on clinically validated mechanisms for cardiovascular diseases. Milestone's lead product is a novel and potent short-acting calcium channel antagonist for the systemic treatment of transient cardiovascular conditions such as atrialarrhythmias and angina. | $17M / Series B / Jun 15, 2015 | |
Thrasos
|
Thrasos is a bio-therapeutics company focused on the discovery and development of targeted therapies for the prevention and treatment of severe organ failure, with a principle focus on kidney disease. The Company's lead therapeutic program, THR-184, is focused on the prevention and treatment of acute kidney injury (AKI). The Company also has apreclinical development program for treating chronic kidney disease (CKD). | $21M / Series D / Mar 31, 2015 | |
Balance Therapeutics
|
Balance Therapeutics is an R&D company focused on developing therapeutics to address conditions of intellectual disability. Balance's pharmacological approach, based on technology licensed from Stanford University has demonstrated the promising potential to address cognitive deficits in animal models of Down syndrome and Alzheimer’sdisease. Clinical trials for the company’s lead product are currently in progress for Down Syndrome. Balance Therapeutics is located in San Bruno, California, and has a wholly-owned subsidiary in Melbourne, Australia. | $18M / Series A / Mar 19, 2015 | |
Aura Biosciences
|
Aura Biosciences is a biotechnology company that focuses on the development of drugs by using tumor-targeted pseudovirions. The company is applying nanotechnology to help fight cancer in the well-studied area of chemotherapeutics and the emerging field of RNAi. By safely eliminating cancer locally, they can treat early and transform the lives ofpeople with a wide range of cancers that are poorly managed today.The company's goal is to treat small ocular melanomas potentially long before the disease progresses and metastasizes to the liver, where it almost always is fatal. Aura Biosciences was founded in 2007 and is headquartered in Cambridge, Massachusetts. | $21M / Series B / Mar 05, 2015 | |
Lumena Pharmaceuticals
|
Lumena Pharmaceuticals is developing oral therapeutics for rare liver diseases to improve liver function, relieve disease symptoms and dramatically impact patient health. The company’s clinical-stage product candidates carry a reduced risk of systemic toxicities by selectively targeting a transporter in the intestine and are designed to beminimally absorbed in the body. Lumena’s lead candidate, LUM001, has been extensively evaluated in other indications across 12 clinical studies in more than 1,400 subjects. Because of the extensive preclinical and clinical data package for a compound at this stage in development, LUM001 is positioned to rapidly progress through the clinic in pediatric and adult patients with several types of cholestatic liver disease. While Lumena’s primary focus is to develop novel treatments for patients with rare liver diseases, the company’s therapeutic approach also has promising potential in the treatment of metabolic diseases affecting the liver, a significant and growing health problem in children and adults. | $45M / Series B / Mar 11, 2014 | |
Envisia Therapeutics
|
As many as 285 million people suffer from disease-related visual impairments and blindness1, but an estimated 80 percent of these visual impairments are actually preventable2. Unfortunately, the safety and effectiveness of many medical therapies for ocular disorders are limited due to poor drug uptake, non-specificity to target tissues, systemicside effects, or poor adherence to therapy. With a rapidly aging population, the unmet medical needs in ocular disease are becoming even more pronounced. As a result, patients and physicians are seeking improved ocular therapeutics that can significantly enhance patient outcomes and convenience. | $25M / Series A / Nov 12, 2013 | |
|
Lumena Pharmaceuticals
|
Lumena Pharmaceuticals is developing oral therapeutics for rare liver diseases to improve liver function, relieve disease symptoms and dramatically impact patient health. The company’s clinical-stage product candidates carry a reduced risk of systemic toxicities by selectively targeting a transporter in the intestine and are designed to beminimally absorbed in the body. Lumena’s lead candidate, LUM001, has been extensively evaluated in other indications across 12 clinical studies in more than 1,400 subjects. Because of the extensive preclinical and clinical data package for a compound at this stage in development, LUM001 is positioned to rapidly progress through the clinic in pediatric and adult patients with several types of cholestatic liver disease. While Lumena’s primary focus is to develop novel treatments for patients with rare liver diseases, the company’s therapeutic approach also has promising potential in the treatment of metabolic diseases affecting the liver, a significant and growing health problem in children and adults. | $23M / Series A / May 08, 2013 | |
Afferent Pharmaceuticals
|
Afferent Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It develops medicines to treat chronic pain by targeting P2X3 receptors in nerve fibers. The company’s AF-219, a compound that completed two Phase 1 clinical studies. Afferent Pharmaceuticals, Inc. was founded in 2009 and is based in San Mateo, California. | $5M / Series B / Apr 01, 2013 | |
| See all 42 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
Health Care Investors
43,014 investors
Biotech Investors
21,775 investors
Biotechnology Investors
19,370 investors
Medical Device Investors
11,047 investors
Health Care VC Funds
32,370 investors
Biotech VC Funds
18,864 investors
Biotechnology VC Funds
17,016 investors
Medical Device VC Funds
9,894 investors
Health Care Investors in United States
21,541 investors
FAQ
What does Pappas Ventures invest in?
Pappas Ventures invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Series B stage. Most of the 42 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Pappas Ventures?
Public channels for Pappas Ventures include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Pappas Ventures?
The team at Pappas Ventures includes Eric W. Linsley (Partner), Ford Worthy (Partner) and Franz Humer (Venture partner and Senior editor), among 8 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
